GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD,
PhD, principal investigator of the G-202 Phase II trial in
hepatocellular carcinoma, will present data from the G-202 Phase I
clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and
Cancer Therapeutics in Boston, MA on Monday, October 21st (http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx).
Dr. Mahalingam will present a poster, “A first-in-human phase 1
clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane
Antigen (PSMA) activated prodrug, in patients with advanced solid
tumors,” in the session from 12:30 – 3:00. Dr. Mahalingam is an
oncologist at the Cancer Therapy & Research Center at The University of
Texas Health Science Center at San Antonio.
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived
cytotoxin (thapsigargin) with a prodrug delivery system that provides
for the targeted release of drug candidates within a tumor. Unlike
typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an
effective approach to kill both fast- and slow-growing cancers.
GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA
which is found at high levels in liver and prostate cancer and in the
vasculature of almost all other solid tumors and is therefore expected
to have efficacy in a wide variety of tumor types.
Data from the G-202 Phase Ib program in solid tumor patients
demonstrated that G-202 is well-tolerated with prolonged disease
stabilization observed in several hepatocellular carcinoma (liver
cancer) patients whose disease had previously worsened on standard
therapy. A Phase II clinical trial in patients with hepatocellular
carcinoma is currently underway.
For more information, please visit the Company’s website: www.genspera.com
or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are
cautioned that such forward-looking statements in this press release
regarding potential applications of GenSpera’s technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional information
on potential factors that could affect our results and other risks and
uncertainties will be detailed from time to time in GenSpera’s periodic
reports filed with the Securities and Exchange Commission.
Copyright Business Wire 2013